KRAS and colorectal carcinoma: To test this, we focused on 11 KRAS mutant CRC cell lines that have been tested in our laboratory and demonstrated consistent sensitivity or resistance across four different MEK inhibitors [TAK-733, AZD6244 [19], PD-0325901 [20] and U0126 [21]] (Table 2).